Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder
- PMID: 35163764
- PMCID: PMC8836876
- DOI: 10.3390/ijms23031844
Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder
Abstract
Bipolar disorder (BD) is characterized by mood changes, including recurrent manic, hypomanic, and depressive episodes, which may involve mixed symptoms. Despite the progress in neurobiological research, the pathophysiology of BD has not been extensively described to date. Progress in the understanding of the neurobiology driving BD could help facilitate the discovery of therapeutic targets and biomarkers for its early detection. Oxidative stress (OS), which damages biomolecules and causes mitochondrial and dopamine system dysfunctions, is a persistent finding in patients with BD. Inflammation and immune dysfunction might also play a role in BD pathophysiology. Specific nutrient supplements (nutraceuticals) may target neurobiological pathways suggested to be perturbed in BD, such as inflammation, mitochondrial dysfunction, and OS. Consequently, nutraceuticals may be used in the adjunctive treatment of BD. This paper summarizes the possible roles of OS, mitochondrial dysfunction, and immune system dysregulation in the onset of BD. It then discusses OS-mitigating strategies that may serve as therapeutic interventions for BD. It also analyzes the relationship between diet and BD as well as the use of nutritional interventions in the treatment of BD. In addition, it addresses the use of lithium therapy; novel antipsychotic agents, including clozapine, olanzapine, risperidone, cariprazine, and quetiapine; and anti-inflammatory agents to treat BD. Furthermore, it reviews the efficacy of the most used therapies for BD, such as cognitive-behavioral therapy, bright light therapy, imagery-focused cognitive therapy, and electroconvulsive therapy. A better understanding of the roles of OS, mitochondrial dysfunction, and inflammation in the pathogenesis of bipolar disorder, along with a stronger elucidation of the therapeutic functions of antioxidants, antipsychotics, anti-inflammatory agents, lithium therapy, and light therapies, may lead to improved strategies for the treatment and prevention of bipolar disorder.
Keywords: anti-inflammatory agents; antipsychotics; bipolar disorder; immune system dysregulation; light therapy; lithium therapy; mitochondrial dysfunctions; nutrients; oxidative stress.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
-
Targeting Mitochondrial Dysfunction for Bipolar Disorder.Curr Top Behav Neurosci. 2021;48:61-99. doi: 10.1007/7854_2020_152. Curr Top Behav Neurosci. 2021. PMID: 33580439 Review.
-
Mitochondrial dysfunction as a critical event in the pathophysiology of bipolar disorder.Mitochondrion. 2021 Mar;57:23-36. doi: 10.1016/j.mito.2020.12.002. Epub 2020 Dec 17. Mitochondrion. 2021. PMID: 33340709 Free PMC article. Review.
-
Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.Curr Drug Metab. 2018;19(8):663-673. doi: 10.2174/1389200219666171227203737. Curr Drug Metab. 2018. PMID: 29283064 Review.
-
[Early intervention in bipolar affective disorders: Why, when and how].Encephale. 2022 Feb;48(1):60-69. doi: 10.1016/j.encep.2021.05.007. Epub 2021 Sep 23. Encephale. 2022. PMID: 34565543 Review. French.
Cited by
-
Neuroprotective effects of dimethyl fumarate against manic-like behavior induced by ketamine in rats.Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3007-3016. doi: 10.1007/s00210-023-02505-6. Epub 2023 Apr 27. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 37103520
-
Pharmacological Mechanism of Herbal Interventions for Bipolar Disorder.Curr Pharm Des. 2024;30(24):1867-1879. doi: 10.2174/0113816128312442240519184440. Curr Pharm Des. 2024. PMID: 38847247 Review.
-
Association between keloid and mental disorders: perspective from genetic evidence.Ann Gen Psychiatry. 2025 Jul 3;24(1):42. doi: 10.1186/s12991-025-00579-5. Ann Gen Psychiatry. 2025. PMID: 40611270 Free PMC article.
-
Causal role of immune cells in bipolar disorder: a Mendelian randomization study.Front Psychiatry. 2024 Aug 16;15:1411280. doi: 10.3389/fpsyt.2024.1411280. eCollection 2024. Front Psychiatry. 2024. PMID: 39220183 Free PMC article.
-
Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation.Brain Sci. 2023 May 11;13(5):784. doi: 10.3390/brainsci13050784. Brain Sci. 2023. PMID: 37239256 Free PMC article. Review.
References
-
- Husain S.F., Tang T.-B., Tam W.W., Tran B.X., Ho C.S., Ho R.C. Cortical haemodynamic response during the verbal fluency task in patients with bipolar disorder and borderline personality disorder: A preliminary functional near—Infrared spectroscopy study. BMC Psychiatry. 2021;21:201. doi: 10.1186/s12888-021-03195-1. - DOI - PMC - PubMed
-
- Muller J.K., Leweke F.M. Bipolar disorder: Clinical overview. Med. Mon. Pharm. 2016;39:363–369. - PubMed
-
- Moreira F.P., Cardoso T.C., Mondin T.C., Wiener C.D., de Mattos Souza L.D., Oses J.P., Jansen K., da Silva R.A. Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder. Psychiatry Clin. Neurosci. 2019;73:590–593. doi: 10.1111/pcn.12896. - DOI - PubMed
-
- Milev R. The role of electroconvulsive therapy in the treatment of bipolar disorder. In: Carvalho A.F., Vieta E., editors. The Treatment of Bipolar Disorder: Integrative Clinical Strategies and Future Directions. Oxford University Press; Oxford, UK: 2017. pp. 408–422.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical